EDAP TMS SA, develops, produces, markets, distributes and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States and internationally. The company is headquartered in Lyon, France.
| Revenue (TTM) | $74.07M |
| Gross Profit (TTM) | $32.15M |
| EBITDA | $-22.19M |
| Operating Margin | -41.30% |
| Return on Equity | -124.00% |
| Return on Assets | -20.30% |
| Revenue/Share (TTM) | $1.98 |
| Book Value | $0.52 |
| Price-to-Book | 16.03 |
| Price-to-Sales (TTM) | 2.19 |
| EV/Revenue | 2.358 |
| EV/EBITDA | 1165.78 |
| Quarterly Earnings Growth (YoY) | -62.20% |
| Quarterly Revenue Growth (YoY) | 13.90% |
| Shares Outstanding | $37.48M |
| Float | $28.45M |
| % Insiders | 6.13% |
| % Institutions | 38.87% |
Volatility is currently contracting
Edap Tms NASDAQ: EDAP used its 2026 FocalTherics Investor Day to outline its shift toward becoming a “high-growth, pure-play robotic focal therapy company,” with management emphasizing the company's Focal One robotic high-intensity focused ultrasound, or HIFU, platform for prostate cancer and future indications.
, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics ™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research activities and physician education focused on the combination of EDAP's Focal One Robotic HIFU and Telix's PSMA PET imaging products in the management of prostate cancer.
, May 13, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Host Investor Day on June 1, 2026 AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and investors at 8:00 am ET on Monday, June 1, 2026. The presentation will be led by members of the Company's Executive Leadership Team and will include remarks from a prominent urologic surgeon and expert in focal therapy and Focal One HIFU.
, May 07, 2026 (GLOBE NEWSWIRE) -- EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue
, April 30, 2026 (GLOBE NEWSWIRE) -- EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One ® Robotic HIFU in Radiorecurrent Prostate Cancer
, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT AUSTIN, Texas, April 16, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2026, before market open on Thursday, May 7, 2026.
EDAP TMS S.A. (EDAP) Q4 2025 Earnings Call Transcript
